• Products
  • Suppliers
  • Sourcing Requests
  • capsule
  • Paracetamol
  • Dexamethasone
  • semaglutide
  • peptides
  • Metformin
  • Ritonavir
  • liraglutide
  • Yaan Times Biotech Co., Ltd
  • Changsha Staherb Natural Ingredients Co., Ltd.
  • PURELIFE BIOTECH CO.,LTD.
  • Biocompounds Pharmaceutical Inc.
  • Xi'an Kaixiang Photoelectric Technology Co., Ltd
  • Apollo Healthcare Resources (Singapore)
  • Shanghai UFU Laboratory Equipment Co.,Itd
  • GN Chemicals CO,Ltd.
Post Sourcing Request Exhibition
  • Roche to buy Ignyta for $1.7 billion pharmatimes
    January 03, 2018
    Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.
  • Roche to Acquire Ignyta in $1.7B Deal contractpharma
    December 28, 2017
  • Roche and Ignyta signs merger agreement biospectrumasia
    December 26, 2017
  • Ignyta's cancer drug entrectinib receives FDA orphan drug status pharmaceutical-technology
    July 12, 2017
    Biotechnology firm Ignyta has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational, orally available, CNS-active tyrosine kinase inhibitor, entrectinib, to treat NTRK fusion-positive solid tumours.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service